Skip to main content

Table 3 Histologic abnormalities of study groups

From: Investigation of potential early Histologic markers of pediatric inflammatory bowel disease

  IBD Control p value
Gastritis 11/18 (61 %) 4/18 (22 %) .020
Duodenitis 4/18 (22 %) 2/19 (11 %) .303
Lymphoid hyperplasia: duodenum 1/18 (6 %) 0/19 (0 %) .486
Lymphoid hyperplasia: cecum 1/8 (13 %) 0/4 (0 %) .667
Lymphoid hyperplasia: terminal ileum 3/14 (21 %) 0/11 (0 %) .158
Basal plasmacytosis: rectosigmoid 2/15 (13 %) 0/14 (0 %) .259
Basal plasmacytosis: transverse colon 1/3 (33 %) 0/4 (0 %) .429
Basal plasmacytosis: cecum 1/8 (13 %) 0/4 (0 %) .667
Cryptitis: colon any area 6/37 (16 %) 3/33 (9 %) .485
Cryptitis: duodenum 2/18 (11 %) 0/19 (0 %) .230
Cryptitis: rectosigmoid 3/15 (20 %) 1/13 (8 %) .356
Cryptitis: left colon 0/2 (0 %) 1/3 (33 %) .600
Cryptitis: transverse colon 1/3 (33 %) 1/4 (25 %) .714
Cryptitis: right colon 1/3 (33 %) 0/2 (0 %) .600
Cryptitis: terminal ileum 1/14 (7 %) 0/11 (0 %) .560
Crypt abscess: colon any area 2/23 (9 %) 0/18 (0 %) .495
Crypt abscess: rectosigmoid 2/15 (13 %) 0/14 (0 %) .259
Crypt abscess: cecum 1/8 (13 %) 0/4 (0 %) .667
Crypt distortion: colon any area 10/29 (34 %) 1/24 (4 %) .008
Crypt distortion: rectosigmoid 2/15 (13 %) 0/14 (0 %) .259
Crypt distortion: transverse colon 1/3 (33 %) 0/4 (0 %) .429
Crypt distortion: right colon 2/3 (67 %) 0/2 (0 %) .300
Crypt distortion: cecum 5/8 (63 %) 1/4 (25 %) .273